ACAD — ACADIA Pharmaceuticals Inc.

ACADIA Pharmaceuticals Inc. Q4 2025 Earnings Call Summary

1. Key Financial Results and Metrics

• Q4 2025 Adjusted Total Revenues: $298 million, a 16% increase year-over-year.
• Full Year 2025 Adjusted Revenues: $1.08 billion, representing a 14% growth from 2024.
• NUPLAZID Net Sales: Q4 at $189 million (up 17% YoY), full year at $692 million (up 15% YoY).
• DAYBUE Net Sales: Q4 at $110 million (up 13% YoY), full year at $391 million (up 12% YoY).
• Gross to Net for NUPLAZID: 29.4% reported, 23.6% adjusted for Q4.
• Cash Balance: $820 million at year-end.
• Tax Benefit: A one-time noncash income tax benefit of approximately $250 million due to the release of a valuation allowance on deferred tax assets.

2. Strategic Updates and Business Highlights

• NUPLAZID: Continued strong performance with a focus on expanding prescriber base and awareness of Parkinson's disease psychosis. The company expects NUPLAZID to reach blockbuster status with projected sales of $1 billion by 2028.
• DAYBUE: Growth driven by expansion into community physician settings and the launch of DAYBUE STIX, a new powder formulation. The company anticipates significant interest and potential patient capture from this new formulation.
• R&D Pipeline: Four unique molecules targeting large markets with a combined peak sales potential of $11 billion. Key upcoming milestones include Phase II readouts for remlifanserin in Alzheimer's disease psychosis expected between August and October 2026.

3. Forward Guidance and Outlook

• 2026 Total Revenue Guidance: Expected between $1.22 billion and $1.28 billion.
• NUPLAZID Guidance: Projected net sales of $760 million to $790 million, reflecting 10% to 14% growth over 2025.
• DAYBUE Guidance: Expected net sales between $460 million and $490 million, driven by DAYBUE STIX and named patient supply programs.
• Long-term Projections: DAYBUE projected global sales of $700 million by 2028, with EU sales representing less than 15% of that total.

4. Bad News, Challenges, or Points of Concern

• Regulatory Setback: Negative trend vote from the CHMP regarding the trofinetide marketing application in the EU, leading to plans for a reexamination.
• IRA Impact: Higher-than-expected invoices from CMS under the Inflation Reduction Act led to a nonrecurring accounting change affecting net sales.
• Market Competition: Potential competition from other treatments, including Cobenfy, which may impact the market landscape for remlifanserin.
• Execution Risks: Ongoing concerns about clinical trial execution and the potential for placebo effects in upcoming studies.

5. Notable Q&A Insights

• Growth Strategy: Management expressed confidence in achieving 2028 sales targets, with NUPLAZID expected to grow in the low to mid-teens and DAYBUE in the low 20% range.
• Patient Compliance: DAYBUE's persistency remains stable, with low discontinuation rates, indicating solid patient adherence.
• Regulatory Pathway: The company is committed to addressing concerns raised by the CHMP regarding DAYBUE and is optimistic about the potential for reexamination to yield a positive outcome.
• Market Expansion: The introduction of DAYBUE STIX is expected to unlock additional patient segments, including treatment-naive patients and those who previously discontinued therapy due to formulation issues.

This summary encapsulates ACADIA's performance and strategic direction while highlighting both opportunities and challenges as the company moves forward.